Uso del producto: Este producto está destinado exclusivamente a la investigación.
Toda la información de los productos de este sitio web tiene fines exclusivamente educativos. Cualquier forma de introducción en el cuerpo de personas o animales está estrictamente prohibida por la ley. Este producto solo debe ser manipulado por profesionales autorizados y cualificados. No es un medicamento, alimento ni cosmético y no debe etiquetarse, utilizarse ni presentarse como tal.
SLU-PP-332 (100mg/capsule), 60 Capsules
Durante el cambio de envase, puedes recibir productos con la etiqueta anterior o con la nueva. La formulación, la pureza y la calidad siguen siendo exactamente las mismas, según nuestros estándares.
- Tarjeta de crédito
- Transferencia bancaria (SEPA inmediata)
- Transferencia bancaria (ACH)
- Wise
- Revolut
- Zelle
- Remitly
- Western Union
- Chime
- Otros
-25% en todo – hasta el 31 de octubre
25% sobre los precios habituales, en sustitución de otras ofertas. Acumulable solo con el descuento crypto.
Envío en el día para pedidos en EE. UU. realizados antes de las 12:00 EST.
Ver la política de envíos →Devoluciones sin complicaciones en 30 días para productos sin abrir.
Ver la política de devoluciones →Cada lote se analiza para comprobar su pureza, potencia y calidad.
Ver resultados de laboratorio →SLU-PP-332 is a selective pan-estrogen receptor-related receptor (ERR) agonist with demonstrated activity across ERRα, ERRβ, and ERRγ subtypes. The compound exhibits properties related to enhanced mitochondrial biogenesis and oxidative phosphorylation in cellular models. Each unit contains 100mg of the active molecule, supplied in 60-count containers for research applications.
The compound is intended exclusively for analytical and laboratory research purposes.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure
Drag to rotate · scroll to zoom| Chemical Formula | C18H14N2O2 |
|---|---|
| Synonyms | 4-Hydroxy-N’-(naphthalen-2-ylmethylene)benzohydrazide |
| Molar Mass | 290.32 g/mol |
| CAS Number | 303760-60-3 |
| PubChem CID | 5338394 |
| Total Compound Content | 6,000 mg (100 mg per capsule) |
| Shelf Life | 36 months |
Results refer to the tested sample. Check the batch and date in the report.
What are estrogen-related receptors (ERRs) and why is SLU-PP-332 significant as a pan-agonist?
ERRα, ERRβ, and ERRγ are orphan nuclear receptors that function as constitutively active transcription factors within the nuclear receptor superfamily. These receptors regulate gene expression through interactions with coactivator proteins and transcriptional regulatory complexes.
SLU-PP-332 is notable for exhibiting activity across all three ERR subtypes, making it a valuable research tool for investigating pan-ERR receptor pharmacology, receptor-coactivator interactions, and the coordinated regulation of ERR-dependent transcriptional signaling networks.
What makes SLU-PP-332 useful for ERR receptor research?
SLU-PP-332 possesses a highly selective pan-ERR activity profile, enabling experimental investigation of ERRα-, ERRβ-, and ERRγ-mediated signaling within a single molecular framework. This characteristic allows researchers to examine receptor activation mechanisms, coactivator recruitment processes, transcriptional control systems, and downstream regulatory pathways associated with ERR signaling.
Its well-characterized pharmacological profile has established it as an important tool for studies of orphan nuclear receptor biology.
How does SLU-PP-332 differ from other nuclear receptor agonists?
SLU-PP-332 selectively targets the estrogen-related receptor family, whereas many other nuclear receptor agonists act through distinct receptor systems with different signaling architectures and transcriptional regulatory mechanisms. This receptor specificity makes SLU-PP-332 useful for comparative investigations of nuclear receptor pharmacology, receptor-ligand interactions, coactivator biology, and the molecular processes governing receptor-mediated transcriptional regulation.
